focus -WSS

focus

author：knowledge 2025-09-03 09:36:56 - browse：17688

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Cancer diagnosis changes perspective doctor, former hospital CEO

WSS

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Medicare Advantage enrollment grows 7.1% to 33.4 million people

NIH chief: government has fallen behind pharma on clinical trials

What is STAT's opinion section for?

explore

focus

focus

Peter Hotez and the public health issue of online harassment

Medicare’s new pay boost for primary care is angering specialists

United colonoscopy coverage change 'may cost lives,' doctors say

Publishing genetic code of viruses could cause disaster

The high cost of giving birth even with insurance

Medicare Advantage enrollment hits roughly 33.4 million

Novavax promises a turnaround & Lilly roils the obesity market

Ohio still needs to do more to protect the right to abortion

Tori Bowie and the unacceptable rates of Black maternal death

Medicare Advantage enrollment grows 7.1% to 33.4 million people

focus

A new drug could help frostbite victims avoid its ravages

Reporting on presidential health from Reagan to Trump and Biden

FDA warns medical device makers about rise in fabricated data

Reporting on presidential health from Reagan to Trump and Biden

Measles policy set amid Florida outbreak alarms vaccine proponents

Elevance, SCAN deals highlight health insurer acquisition scrutiny

explore

focus

entertainment

leisure time